DeepVerge has announced that the first six installations of Modern Water’s post-pandemic Microtox®PD wastewater pathogen detection system have been deployed to various sites in the UK, as part of the Environmental Monitoring for Health Protection (‘EMHP’) programme.
A team from the Group’s 100%-owned subsidiary are also working with the Joint Biosecurity Centre, part of NHS Test & Trace service, to trial a national system of ‘sentinel’ sewage works that are designed to act as an early warning system to identify spikes of the most common variants of the SARS-CoV-2 virus. Wastewater surveillance testing presently takes place at c.470 sites across England between four and seven times per week, targeting the existence of a range of viruses and chemicals that are potentially hazardous to public health.
The UK Health Security Agency’s stated post-Pandemic requirement, however, is for the development of locally deployed monitoring sensors that provide real-time wastewater-based epidemiology (‘WBE’) as a service, a capability that is uniquely available through Modern Water’s proven technologies which offer unrivalled, networked and AI-driven early-warning detection. Indeed, the fact that the Agency sees fit to present an image of Modern Water’s onsite equipment within its recent publications, ‘Wastewater monitoring during and after a pandemic’, suggests Microtox®PD may already be part of its preferred solution.
(Please note that TPI’s valuation is based on financial modelling and there is no guarantee that such a valuation will ever be realised, therefore please do not base investment decisions on this valuation alone. Also please note that past performance is not a reliable indicator of future results.)
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to DeepVerge plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2022 Turner Pope Investments (TPI) Limited, all rights reserved.
